

# VERTEX PHARMACEUTICALS INC / MA

Reported by  
**SMITH IAN F**

## **FORM 4**

(Statement of Changes in Beneficial Ownership)

Filed 10/31/17 for the Period Ending 10/31/17

Address	50 NORTHERN AVENUE BOSTON, MA, 02210
Telephone	6173416393
CIK	0000875320
Symbol	VRTX
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person *</b>  <b>SMITH IAN F</b>  (Last) (First) (Middle)  <b>C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE</b>  (Street)  <b>BOSTON, MA 02210</b>  (City) (State) (Zip)	<b>2. Issuer Name and Ticker or Trading Symbol</b>  <b>VERTEX PHARMACEUTICALS INC / MA [ VRTX ]</b>	<b>5. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable)  <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> <b>X</b> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>EVP, COO</b>
<b>3. Date of Earliest Transaction (MM/DD/YYYY)</b>  <p align="center"><b>10/31/2017</b></p>		<b>6. Individual or Joint/Group Filing (Check Applicable Line)</b>  <input type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
<b>4. If Amendment, Date Original Filed (MM/DD/YYYY)</b>		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/31/2017		S (1)		1700	D	\$142.40 (2)(3)	114188	D	
Common Stock	10/31/2017		S (1)		5200	D	\$143.47 (3)(4)	108988	D	
Common Stock	10/31/2017		S (1)		32945	D	\$144.47 (3)(5)	76043	D	
Common Stock	10/31/2017		S (1)		22464	D	\$145.26 (3)(6)	53579	D	
Common Stock	10/31/2017		S (1)		5200	D	\$146.39 (3)(7)	48379	D	
Common Stock	10/31/2017		S (1)		3500	D	\$147.40 (3)(8)	44879	D	
Common Stock	10/31/2017		S (1)		3791	D	\$148.26 (3)(9)	41088	D	
Common Stock	10/31/2017		S (1)		200	D	\$149.34	40888	D	
Common Stock								5306	I	401(k)

**Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date				

**Explanation of Responses:**

- (1) Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$142.40 (range \$141.83 to \$142.75).
- (3) Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$143.47 (range \$142.91 to \$143.85).
- (5) Open market sales reported on this line occurred at a weighted average price of \$144.47 (range \$143.91 to \$144.89).
- (6) Open market sales reported on this line occurred at a weighted average price of \$145.26 (range \$144.93 to \$145.87).
- (7) Open market sales reported on this line occurred at a weighted average price of \$146.39 (range \$145.30 to \$146.92).
- (8) Open market sales reported on this line occurred at a weighted average price of \$147.40 (range \$146.93 to \$147.90).
- (9) Open market sales reported on this line occurred at a weighted average price of \$148.26 (range \$147.93 to \$148.70).

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>SMITH IAN F</b> <b>C/O VERTEX PHARMACEUTICALS INCORPORATED</b> <b>50 NORTHERN AVENUE</b> <b>BOSTON, MA 02210</b>			<b>EVP, COO</b>	

**Signatures**

/s/ Omar White, Attorney-in-Fact

10/31/2017

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.